dc.creatorSampaio-Barros P.D.
dc.creatorZimmermann A.F.
dc.creatorMuller C.S.
dc.creatorBorges C.T.L.
dc.creatorFreire E.A.M.
dc.creatorMaretti G.B.
dc.creatorNeto J.F.M.
dc.creatorSalgado M.C.F.
dc.creatorda Cunha Sauma M.F.L.
dc.creatorde Azevedo M.N.L.
dc.creatorFontenelle S.
dc.creatorKayser C.
dc.date2013
dc.date2015-06-25T19:14:06Z
dc.date2015-11-26T15:11:53Z
dc.date2015-06-25T19:14:06Z
dc.date2015-11-26T15:11:53Z
dc.date.accessioned2018-03-28T22:21:59Z
dc.date.available2018-03-28T22:21:59Z
dc.identifier
dc.identifierRevista Brasileira De Reumatologia. , v. 53, n. 3, p. 258 - 275, 2013.
dc.identifier
dc.identifier10.1590/S0482-50042013000300004
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84884953100&partnerID=40&md5=6de4ec43ab30bde4ac045cbb91322f37
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/89027
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/89027
dc.identifier2-s2.0-84884953100
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1258250
dc.description[No abstract available]
dc.description53
dc.description3
dc.description258
dc.description275
dc.descriptionJohnson, S.R., Feldman, B.M., Hawker, G.A., Classification criteria for systemic sclerosis subsets (2007) J Rheumatol, 34, pp. 1855-1863
dc.descriptionMasi, A.T., Rodnan, G.P., Medsger Jr., T.A., Altman, R.D., D'Angelo, W.A., Fries, J.F., Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980) Arthritis Rheum, 23, pp. 581-590
dc.descriptionLeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger Jr., T.A., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis (1988) J Rheumatol, 15, pp. 202-205
dc.descriptionWalker, J.G., Pope, J., Baron, M., Leclercq, S., Hudson, M., Taillefer, S., The development of systemic sclerosis classification criteria (2007) Clin Rheumatol, 26, pp. 1401-1409
dc.descriptionWalker, U.A., Tyndall, A., Czirjak, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base (2007) Ann Rheum Dis, 66, pp. 754-763
dc.descriptionLeRoy, E.C., Medsger Jr., T.A., Criteria for the classification of early systemic sclerosis (2001) J Rheumatol, 28, pp. 1573-1576
dc.descriptionPoormoghim, H., Lucas, M., Fertig, N., Medsger Jr., T.A., Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients (2000) Arthritis Rheum, 43, pp. 444-451
dc.descriptionAvouac, J., Fransen, J., Walker, U.A., Riccieri, V., Smith, V., Muller, C., Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group (2011) Ann Rheum Dis, 70, pp. 476-481
dc.descriptionPavlov-Dolijanovic, S., Damjanov, N.S., Stojanovic, R.M., Vujasinovictupar, N.Z., Stanisavljevic, D.M., Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon (2012) Rheumatol Int, 32, pp. 3039-3045
dc.descriptionMcGill, N.W., Gow, P.J., Nailfold capillaroscopy: a blinded study of its discriminatory value in scleroderma, systemic lupus erythematosus, and rheumatoid arthritis (1986) Aust N Z J Med, 16, pp. 457-460
dc.descriptionIngegnoli, F., Boracchi, P., Gualtierotti, R., Biganzoli, E.M., Zeni, S., Lubatti, C., Fantini, F., Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nailfold capillaroscopy (2010) Rheumatology (Oxford), 49, pp. 797-805
dc.descriptionCutolo, M., Sulli, A., Pizzorni, C., Accardo, S., Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis (2000) J Rheumatol, 27, pp. 155-160
dc.descriptionWildt, M., Wuttge, D.M., Hesselstrand, R., Scheja, A., Assessment of capillary density in systemic sclerosis with three different capillaroscopic methods (2012) Clin Exp Rheumatol, 30 (2 SUPPL. 71), pp. S50-S54
dc.descriptionMuroi, E., Hara, T., Yanaba, K., Ogawa, F., Yoshizaki, A., Takenaka, M., Shimizu, K., Sato, S., A portable dermatoscope for easy, rapid examination of periungueal nailfold capillary changes in patients with systemic sclerosis (2011) Rheumatol Int, 31, pp. 1601-1606
dc.descriptionSebastiani, M., Manfredi, A., Colaci, M., D'Amico, R., Malagoli, V., Giuggioli, D., Ferri, C., Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients (2009) Arthritis Rheum, 61 (5), pp. 688-694
dc.descriptionSebastiani, M., Manfredi, A., Vukatana, G., Moscatelli, S., Riato, L., Bocci, M., Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study (2012) Ann Rheum Dis, 71, pp. 67-70
dc.descriptionBredemeier, M., Xavier, R.M., Capobianco, K.G., Restelli, V.G., Rohde, L.E., Pinotti, A.F., Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis (2004) J Rheumatol, 31, pp. 286-294
dc.descriptionJoyal, F., Choquette, D., Roussin, A., Levington, C., Senécal, J.L., Evaluation of the severity of systemic sclerosis by nailfold capillary microscopy in 112 patients (1992) Angiology, 43 (3 PART 1), pp. 203-210
dc.descriptionRiboldi, P., Asero, R., Origgi, L., Crespi, S., Meroni, P.L., Sguotti, C., Sabbadini, M.G., Antinuclear antibodies in progressive systemic sclerosis (1985) Clin Exp Rheumatol, 3, pp. 205-211
dc.descriptionKipnis, R.J., Craft, J., Hardin, J.A., The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays (1990) Arthritis Rheum, 33, pp. 1431-1437
dc.descriptionSimeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, C., Espinosa-Garriga, G., Ramos-Casals, M., Campillo-Grau, M., Registry of the Spanish Network for Systemic Sclerosis: Clinical pattern according to cutaneous subsets and immunological status (2012) Semin Arthritis Rheum, 41, pp. 789-800
dc.descriptionHunzelmann, N., Genth, E., Krieg, T., Lehmacher, W., Melchers, I., Meurer, M., Registry of the German Network for Systemic Scleroderma: The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement (2008) Rheumatology (Oxford), 47, pp. 1185-1192
dc.descriptionAeschlimann, A., Meyer, O., Bourgeois, P., Haim, T., Belmatoug, N., Palazzo, E., Kahn, M.F., Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations (1989) Ann Rheum Dis, 48, pp. 992-997
dc.descriptionHarvey, G.R., Butts, S., Rands, A.L., Patel, Y., McHugh, N.J., Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis (1999) Clin Exp Immunol, 117, pp. 395-402
dc.descriptionTan, F.K., Arnett, F.C., Reveille, J.D., Ahn, C., Antohi, S., Sasaki, T., Nishi Bona, C.A., Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles (2000) Arthritis Rheum, 43, pp. 2464-2471
dc.descriptionTan, F.K., Arnett, F.C., Antohi, S., Saito, S., Mirarchi, A., Spiera, H., Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases (1999) J Immunol, 163, pp. 1066-1072
dc.descriptionSteen, V.D., Autoantibodies in systemic sclerosis (2005) Semin Arthritis Rheum, 35, pp. 35-42
dc.descriptionWalker, J.G., Fritzler, M.J., Update on autoantibodies on systemic sclerosis (2007) Curr Opin Rheumatol, 19, pp. 580-591
dc.descriptionKaldas, M., Khanna, P.P., Furst, D.E., Clements, P.J., Wong, W.K., Seibold, J.R., Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials (2009) Rheumatology (Oxford), 48, pp. 1143-1146
dc.descriptionMerkel, P.A., Silliman, N.P., Denton, C.P., Furst, D.E., Khanna, D., Emery, P., Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial (2008) Arthritis Rheum, 59, pp. 699-705
dc.descriptionvan den Hoogen, F.H., Boerbooms, A.M., Swaak, A.J., Rasker, J.J., van Lier, H.J., van de Putte, L.B., Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial (1996) Br J Rheumatol, 35, pp. 364-372
dc.descriptionPope, J.E., Bellamy, N., Seibold, J.R., Baron, M., Ellman, M., Carette, S., A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma (2001) Arthritis Rheum, 44, pp. 1351-1358
dc.descriptionClements, P.J., Furst, D.E., Wong, W.K., Mayes, M., White, B., Wigley, F., High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial (1999) Arthritis Rheum, 42, pp. 1194-1203
dc.descriptionSeibold, J.R., Korn, J.H., Simms, R., Clements, P.J., Moreland, L.W., Mayes, M.D., Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial (2000) Ann Intern Med, 132, pp. 871-879
dc.descriptionKhanna, D., Clements, P.J., Furst, D.E., Korn, J.H., Ellman, M., Rothfield, N., Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebocontrolled trial (2009) Arthritis Rheum, 60, pp. 1102-1111
dc.descriptionPostlethwaite, A.E., Wong, W.K., Clements, P., Chatterjee, S., Fessler, B.J., Kang, A.H., A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease (2008) Arthritis Rheum, 58, pp. 1810-1822
dc.descriptionKawald, A., Burmester, G.R., Huscher, D., Sunderkötter, C., Riemekasten, G., Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study (2008) J Rheumatol, 35, pp. 1830-1837
dc.descriptionTashkin, D.P., Elashoff, R., Clements, P.J., Goldin, J., Roth, M.D., Furst, D.E., Cyclophosphamide versus placebo in scleroderma lung disease (2006) N Engl J Med, 354, pp. 2655-2666
dc.descriptionClements, P.J., Roth, M.D., Elashoff, R., Tashkin, D.P., Goldin, J., Silver, R.M., Scleroderma lung study (SLS): differences in presentation and course of patients with limited versus diffuse systemic sclerosis (2007) Ann Rheum Dis, 66, pp. 1641-1647
dc.descriptionMendoza, F.A., Nagle, S.J., Lee, J.B., Jimenez, S.A., A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset (2012) J Rheumatol, 39, pp. 1241-1247
dc.descriptionDaoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study (2010) Rheumatology (Oxford), 49, pp. 271-280
dc.descriptionDaoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Paliogianni, F., Sirinian, C., Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis (2012) Clin Exp Rheumatol, 30 (2 SUPPL. 71), pp. S17-S22
dc.descriptionSpiera, R.F., Gordon, J.K., Mersten, J.N., Magro, C.M., Mehta, M., Wildman, H.F., Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial (2011) Ann Rheum Dis, 70, pp. 1006-1009
dc.descriptionKhanna, D., Saggar, R., Mayes, M.D., Abtin, F., Clements, P.J., Maranian, P., A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease (2011) Arthritis Rheum, 63, pp. 3540-3546
dc.descriptionBerger, R.G., Featherstone, G.L., Raasch, R.H., McCartney, W.H., Hadler, N.M., Treatment of calcinosis universalis with lowdose warfarin (1987) Am J Med, 83, pp. 72-76
dc.descriptionYoshida, S., Torikai, K., The effects of warfarin on calcinosis in a patient with systemic sclerosis (1993) J Rheumatol, 20, pp. 1233-1235
dc.descriptionCukierman, T., Elinav, E., Korem, M., Chajek-Shaul, T., Low dose warfarin treatment for calcinosis in patients with systemic sclerosis (2004) Ann Rheum Dis, 63, pp. 1341-1343
dc.descriptionLassoued, K., Saiag, P., Anglade, M.C., Roujeau, J.C., Touraine, R.L., Failure of warfarin in treatment of calcinosis universalis (1988) Am J Med, 84, pp. 795-796
dc.descriptionPalmieri, G.M., Sebes, J.I., Aelion, J.A., Moinuddin, M., Ray, M.W., Wood, G.C., Treatment of calcinosis with diltiazem (1995) Arthritis Rheum, 38, pp. 1646-1654
dc.descriptionVayssairat, M., Hidouche, D., Abdoucheli-Baudot, N., Gaitz, J.P., Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? (1998) Ann Rheum Dis, 57, pp. 252-254
dc.descriptionRobertson, L.P., Marshall, R.W., Hickling, P., Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline (2003) Ann Rheum Dis, 62, pp. 267-269
dc.descriptionFuchs, D., Fruchter, L., Fishel, B., Holtzman, M., Yaron, M., Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis (1986) Clin Rheumatol, 5, pp. 527-530
dc.descriptionDaoussis, D., Antonopoulos, I., Liossis, S.N., Yiannopoulos, G., Andonopoulos, A.P., Treatment of systemic sclerosisassociated calcinosis: A case report of rituximab-induced regression of CREST-related calcinosis and review of the literature (2012) Semin Arthritis Rheum, 41, pp. 822-829
dc.descriptionSaddic, N., Miller, J.J., Miller 3rd, O.F., Clarke, J.T., Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome (2009) Arch Dermatol, 145, pp. 212-213
dc.descriptionBottomley, W.W., Goodfield, M.J., Sheehan-Dare, R.A., Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser (1996) Br J Dermatol, 135, pp. 302-304
dc.descriptionSparsa, A., Lesaux, N., Kessler, E., Bonnetblanc, J.M., Blaise, S., Lebrun-Ly, V., Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy (2005) J Am Acad Dermatol, 53 (5 SUPPL. 1), pp. S263-S265
dc.descriptionThompson, A.E., Shea, B., Welch, V., Fenlon, D., Pope, J.E., Calciumchannel blockers for Raynaud's phenomenon in systemic sclerosis (2001) Arthritis Rheum, 44, pp. 1841-1847
dc.descriptionKahan, A., Amor, B., Menkès, C.J., Weber, S., Guérin, F., Degeorges, M., Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial (1987) Angiology, 38, pp. 333-337
dc.descriptionKahan, A., Amor, B., Menkes, C.J., A randomised doubleblind trial of diltiazem in the treatment of Raynaud's phenomenon (1985) Ann Rheum Dis, 44, pp. 30-33
dc.descriptionHummers, L.K., Wigley, F.M., Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma (2003) Rheum Dis Clin North Am, 29, pp. 293-313
dc.descriptionWigley, F.M., Wise, R.A., Seibold, J.R., McCloskey, D.A., Kujala, G., Medsger Jr., T.A., Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis.A multicenter, placebo-controlled, double-blind study (1994) Ann Intern Med, 120, pp. 199-206
dc.descriptionWigley, F.M., Korn, J.H., Csuka, M.E., Medsger Jr., T.A., Rothfield, N.F., Ellman, M., Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study (1998) Arthritis Rheum, 41, pp. 670-677
dc.descriptionScorza, R., Caronni, M., Mascagni, B., Berruti, V., Bazzi, S., Micallef, E., Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study (2001) Clin Exp Rheumatol, 19, pp. 503-508
dc.descriptionRademaker, M., Cooke, E.D., Almond, N.E., Beacham, J.A., Smith, R.E., Mant, T.G., Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study (1989) BMJ, 298, pp. 561-564
dc.descriptionPope, J., Fenlon, D., Thompson, A., Shea, B., Furst, D., Wells, G., Prazosin for Raynaud's phenomenon in progressive systemic sclerosis (2000) Cochrane Database Syst Rev, (2). , CD000956
dc.descriptionSurwit, R.S., Gilgor, R.S., Allen, L.M., Duvic, M., A doubleblind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma (1984) Arch Dermatol, 120, pp. 329-331
dc.descriptionNguyen, V.A., Eisendle, K., Gruber, I., Hugl, B., Reider, D., Reider, N., Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study (2010) Rheumatology (Oxford), 49, pp. 583-587
dc.descriptionGliddon, A.E., Doré, C.J., Black, C.M., McHugh, N., Moots, R., Denton, C.P., Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril (2007) Arthritis Rheum, 56, pp. 3837-3846
dc.descriptionDziadzio, M., Denton, C.P., Smith, R., Howell, K., Blann, A., Bowers, E., Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteenweek, randomized, parallel-group, controlled trial (1999) Arthritis Rheum, 42, pp. 2646-2655
dc.descriptionShenoy, P.D., Kumar, S., Jha, L.K., Choudhary, S.K., Singh, U., Misra, R., Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a doubleblind randomized cross-over trial (2010) Rheumatology (Oxford), 49, pp. 2420-2428
dc.descriptionSchiopu, E., Hsu, V.M., Impens, A.J., Rothman, J.A., McCloskey, D.A., Wilson, J.E., Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis (2009) J Rheumatol, 36, pp. 2264-2268
dc.descriptionDe La Veja, A.J., Derk, C.T., Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication (2009) Expert Opin Invest Drugs, 18, pp. 23-29
dc.descriptionHerrick, A.L., van den Hoogen, F., Gabrielli, A., Tamimi, N., Reid, C., O'Connell, D., Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis (2011) Arthritis Rheum, 63, pp. 775-782
dc.descriptionPope, J., Fenlon, D., Thompson, A., Shea, B., Furst, D., Wells, G., Silman, A., Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis (2000) Cochrane Database Syst Rev, (2). , CD000955
dc.descriptionLukác, J., Rovenskỳ, J., Tauchmannová, H., Zitnan, D., Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial (1985) Drugs Exp Clin Res, 11, pp. 659-663
dc.descriptionAbou-Raya, A., Abou-Raya, S., Helmii, M., Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers (2008) J Rheumatol, 35, pp. 1801-1808
dc.descriptionHerrick, A.L., Hollis, S., Schofield, D., Rieley, F., Blann, A., Griffin, K., A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis (2000) Clin Exp Rheumatol, 18, pp. 349-356
dc.descriptionWigley, F.M., Seibold, J.R., Wise, R.A., McCloskey, D.A., Dole, W.P., Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis (1992) J Rheumatol, 19 (9), pp. 1407-1414
dc.descriptionLangevitz, P., Buskila, D., Lee, P., Urowitz, M.B., Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions (1989) J Rheumatol, 16, pp. 1433-1435
dc.descriptionMarasini, B., Massarotti, M., Bottasso, B., Coppola, R., Papa, N.D., Maglione, W., Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon (2004) Scand J Rheumatol, 33, pp. 253-256
dc.descriptionMatucci-Cerinic, M., Denton, C.P., Furst, D.E., Mayes, M.D., Hsu, V.M., Carpentier, P., Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial (2011) Ann Rheum Dis, 70, pp. 32-38
dc.descriptionKorn, J.H., Mayes, M., Matucci Cerinic, M., Rainisio, M., Pope, J., Hachulla, E., Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist (2004) Arthritis Rheum, 50, pp. 3985-3993
dc.descriptionBrueckner, C.S., Becker, M.O., Kroencke, T., Huscher, D., Scherer, H.U., Worm, M., Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study (2010) Ann Rheum Dis, 69, pp. 1475-1478
dc.descriptionMercado, U., Arroyo de Anda, R., Avendaño, L., Araiza-Casillas, R., Avendaño-Reyes, M., Metoclopramide response in patients with early diffuse systemic sclerosis.Effects on esophageal motility abnormalities (2005) Clin Exp Rheumatol, 23, pp. 685-688
dc.descriptionJohnson, D.A., Drane, W.E., Curran, J., Benjamin, S.B., Chobanian, S.J., Karvelis, K., Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities (1987) Arch Intern Med, 147, pp. 1597-1601
dc.descriptionNikou, G.C., Toumpanakis, C., Katsiari, C., Charalambopoulos, D., Sfikakis, P.P., Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients (2007) J Clin Rheumatol, 13, pp. 119-123
dc.descriptionVerne, G.N., Eaker, E.Y., Hardy, E., Sninsky, C.A., Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction (1995) Dig Dis Sci, 40, pp. 1892-1901
dc.descriptionMarie, I., Dominique, S., Levesque, H., Ducrotté, P., Denis, P., Hellot, M.F., Esophageal involvement and pulmonary manifestations in systemic sclerosis (2001) Arthritis Rheum, 45, pp. 346-354
dc.descriptionJaniak, P., Thumshirn, M., Menne, D., Fox, M., Halim, S., Fried, M., Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis-a randomized controlled, cross-over trial (2007) Aliment Pharmacol Ther, 26, pp. 1259-1265
dc.descriptionShoenut, J.P., Wieler, J.A., Micflikier, A.B., The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole (1993) Aliment Pharmacol Ther, 7, pp. 509-513
dc.descriptionPakozdi, A., Wilson, H., Black, C.M., Denton, C.P., Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? (2009) Clin Exp Rheumatol, 27 (3 SUPPL. 54), pp. 5-8
dc.descriptionWipff, J., Coriat, R., Masciocchi, M., Caramaschi, P., Derk, C.T., Hachulla, E., Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study (2011) Rheumatology (Oxford), 50, pp. 1440-1444
dc.descriptionKent, M.S., Luketich, J.D., Irshad, K., Awais, O., Alvelo-Rivera, M., Churilla, P., Comparison of surgical approaches to recalcitrant gastroesophageal reflux disease in the patient with scleroderma (2007) Ann Thorac Surg, 84, pp. 1710-1715
dc.descriptionLundberg, A.C., Akesson, A., Akesson, B., Dietary intake and nutritional status in patients with systemic sclerosis (1992) Ann Rheum Dis, 51, pp. 1143-1148
dc.descriptionBaron, M., Hudson, M., Steele, R., Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database (2009) J Rheumatol, 36, pp. 2737-2743. , Canadian Scleroderma Research Group
dc.descriptionCliff, I.S., Herber, R., Demis, D.J., Control of malabsorption in scleroderma (1966) J Invest Dermatol, 47, pp. 475-483
dc.descriptionAlpert, L.I., Warner, R.R., Systemic sclerosis: case presenting with tetracycline-responsive malabsorption syndrome (1968) Am J Med, 45, pp. 468-473
dc.descriptionBrown, M., Teubner, A., Shaffer, J., Herrick, A.L., Home parenteral nutrition-an effective and safe long-term therapy for systemic sclerosis-related intestinal failure (2008) Rheumatology (Oxford), 47, pp. 176-179
dc.descriptionParodi, A., Sessarego, M., Greco, A., Bazzica, M., Filaci, G., Setti, M., Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication (2008) Am J Gastroenterol, 103, pp. 1257-1262
dc.descriptionSchnabel, A., Reuter, M., Gross, W.L., Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases (1998) Arthritis Rheum, 41, pp. 1215-1220
dc.descriptionYiannopoulos, G., Pastromas, V., Antonopoulos, I., Katsiberis, G., Kalliolias, G., Liossis, S.N., Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease (2007) Rheumatol Int, 27, pp. 357-361
dc.descriptionDomiciano, D.S., Bonfá, E., Borges, C.T., Kairalla, R.A., Capelozzi, V.L., Parra, E., A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma (2011) Clin Rheumatol, 30, pp. 223-229
dc.descriptionNannini, C., West, C.P., Erwin, P.J., Matteson, E.L., Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies (2008) Arthritis Res Ther, 10, pp. R124
dc.descriptionTochimoto, A., Kawaguchi, Y., Hara, M., Tateishi, M., Fukasawa, C., Takagi, K., Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up (2011) Mod Rheumatol, 21, pp. 296-301
dc.descriptionSeibold, J.R., Denton, C.P., Furst, D.E., Guillevin, L., Rubin, L.J., Wells, A., Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis (2010) Arthritis Rheum, 62, pp. 2101-2108
dc.descriptionNithyanova, S.I., Brough, G.M., Black, C.M., Denton, C.P., Mycophenolate mofetil in diffuse cutaneous systemioc sclerosis-a retrospective analysis (2007) Rheumatology (Oxford), 46, pp. 442-445
dc.descriptionAvouac, J., Airò, P., Meune, C., Beretta, L., Dieude, P., Caramaschi, P., Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies (2010) J Rheumatol, 37 (11), pp. 2290-2298. , PMID: 20810505
dc.descriptionGaliè, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A., Guidelines for the diagnosis and treatment of pulmonary hypertension (2009) Eur Heart J, 30 (20), pp. 2493-2537
dc.descriptionBadesch, D.B., Tapson, V.F., McGoon, M.D., Brundage, B.H., Rubin, L.J., Wigley, F.M., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial (2000) Ann Intern Med, 132, pp. 425-434
dc.descriptionCaravita, S., Wu, S.C., Secchi, M.B., Dadone, B., Bencini, C., Pierini, S., Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease (2011) Eur J Int Med, 22, pp. 518-521
dc.descriptionChannick, R.N., Simonneau, G., Sitbon, O., Robbins, I.M., Frost, A., Tapson, V.F., Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study (2001) Lancet, 358, pp. 1119-1123
dc.descriptionRubin, L.J., Badesch, D.B., Barst, R.J., Galie, N., Black, C.M., Keogh, A., Bosentan therapy for pulmonary arterial hypertension (2002) N Engl J Med, 346, pp. 896-903
dc.descriptionGaliè, N., Olschewski, H., Oudiz, R.J., Torres, F., Frost, A., Ghofrani, H.A., Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 (2008) Circulation, 117, pp. 3010-3019
dc.descriptionSaggar, R., Khanna, D., Shapiro, S., Furst, D.E., Maranian, P., Clements, P., Effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: A prospective single-center, open-label pilot study (2012) Arthritis Rheum, 64, pp. 4072-4077
dc.descriptionGaliè, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D., Sildenafil citrate therapy for pulmonary arterial hypertension (2005) N Engl J Med, 353, pp. 2148-2157
dc.descriptionBadesch, D.B., Hill, N.S., Burgess, G., Rubin, L.J., Barst, R.J., Galiè, N., Sildenafil for pulmonary arterial hypertension associated with connective tissue disease (2007) J Rheumatol, 34, pp. 2417-2422
dc.descriptionGaliè, N., Brundage, B.H., Ghofrani, H.A., Oudiz, R.J., Simonneau, G., Safdar, Z., Tadalafil therapy for pulmonary arterial hypertension (2009) Circulation, 119, pp. 2894-2903
dc.descriptionDeMarco, P.J., Weisman, M.H., Seibold, J.R., Furst, D.E., Wong, W.K., Hurwitz, E.L., Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial (2002) Arthritis Rheum, 46, pp. 2983-2989
dc.descriptionWalker, J.G., Ahern, M.J., Smith, M.D., Coleman, M., Pile, K., Rischmueller, M., Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment (2003) Intern Med J, 33, pp. 216-220
dc.descriptionPenn, H., Howie, A.J., Kingdon, E.J., Bunn, C.C., Stratton, R.J., Black, C.M., Scleroderma renal crisis: patient characteristics and long-term outcomes (2007) QJM, 100, pp. 485-494
dc.descriptionTeixeira, L., Mouthon, L., Mahr, A., Berezné, A., Agard, C., Mehrenberger, M., Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients (2008) Ann Rheum Dis, 67, pp. 110-116
dc.descriptionHudson, M., Baron, M., Lo, E., Weinfeld, J., Furst, D.E., Khanna, D., An international, web-based, prospective cohort study to determine whether the use of ACE inhibitors prior to the onset of scleroderma renal crisis is associated with worse outcomes-methodology and preliminary results (2010) Int J Rheumatol, 2010, p. 347402. , doi:10.1155/2010/347402. Epub 2010 Sep 14
dc.descriptionHesselstrand, R., Scheja, A., Wuttge, D., Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor (2012) Scand J Rheumatol, 41, pp. 39-43
dc.descriptionFerri, C., Valentini, G., Cozzi, F., Sebastiani, M., Michelassi, C., La Montagna, G., Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients (2002) Medicine, 81, pp. 139-153
dc.descriptionScussel-Lonzetti, L., Joyal, F., Raynauld, J.P., Roussin, A., Rich, E., Goulet, J.R., Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival (2002) Medicine, 81, pp. 154-167
dc.descriptionIoannidis, J.P., Vlachoyiannopoulos, P.G., Haidich, A.B., Medsger Jr., T.A., Lucas, M., Michet, C.J., Mortality in systemic sclerosis: an international meta-analysis of individual patient data (2005) Am J Med, 118, pp. 2-10
dc.descriptionSampaio-Barros, P.D., Bortoluzzo, A.B., Marangoni, R.G., Rocha, L.F., Del Rio, A.P., Samara, A.M., Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients (2012) J Rheumatol, 39, pp. 1971-1978
dc.descriptionMontisci, R., Vacca, A., Garau, P., Colonna, P., Ruscazio, M., Passiu, G., Detection of early impairment of coronary flow reserve in patients with systemic sclerosis (2003) Ann Rheum Dis, 62, pp. 890-893
dc.descriptionSulli, A., Ghio, M., Bezante, G.P., Deferrari, L., Craviotto, C., Sebastiani, V., Blunted coronary flow reserve in systemic sclerosis (2004) Rheumatology (Oxford), 43 (4), pp. 505-509
dc.descriptionKahan, A., Allanore, Y., Primary myocardial involvement in systemic sclerosis (2006) Rheumatology (Oxford), 45 (SUPPL. 4), pp. iv14-7
dc.descriptionIshida, R., Murata, Y., Sawada, Y., Nishioka, K., Shibuya, H., Thallium-201 myocardial SPET in patients with collagen disease (2000) Nucl Med Commun, 21, pp. 729-734
dc.descriptionAkram, M.R., Handler, C.E., Williams, M., Carulli, M.T., Andron, M., Black, C.M., Angiographically proven coronary artery disease in scleroderma (2006) Rheumatology (Oxford), 45, pp. 1395-1398
dc.descriptionKahan, A., Devaux, J.Y., Amor, B., Menkes, C.J., Weber, S., Foult, J.M., Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma (1986) Ann Rheum Dis, 45, pp. 718-725
dc.descriptionKahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Nitenberg, A., Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis (1986) N Engl J Med, 314, pp. 1397-1402
dc.descriptionKahan, A., Devaux, J.Y., Amor, B., Menkes, C.J., Weber, S., Venot, A., Nicardipine improves myocardial perfusion in systemic sclerosis (1988) J Rheumatol, 15, pp. 1395-1400
dc.descriptionKahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Venot, A., The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis (1990) Clin Pharmacol Ther, 47, pp. 483-489
dc.descriptionDuboc, D., Kahan, A., Maziere, B., Loc'h, C., Crouzel, C., Menkès, C.J., The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study (1991) Arthritis Rheum, 34, pp. 198-203
dc.descriptionVignaux, O., Allanore, Y., Meune, C., Pascal, O., Duboc, D., Weber, S., Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis (2005) Ann Rheum Dis, 64, pp. 1268-1273
dc.descriptionKahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Guérin, F., Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis (1990) J Cardiovasc Pharmacol, 15, pp. 249-253
dc.descriptionHegedüs, I., Czirják, L., Left ventricular wall thickness and disease duration in systemic sclerosis (1993) Postgrad Med J, 69, pp. 285-290
dc.descriptionMeune, C., Allanore, Y., Pascal, O., Devaux, J.Y., Dessault, O., Duboc, D., Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study (2005) Eur J Echocardiogr, 6, pp. 351-357
dc.descriptionMeune, C., Avouac, J., Wahbi, K., Cabanes, L., Wipff, J., Mouthon, L., Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients (2008) Arthritis Rheum, 58, pp. 1803-1809
dc.descriptionMeune, C., Allanore, Y., Devaux, J.Y., Dessault, O., Duboc, D., Weber, S., High prevalence of right ventricular systolic dysfunction in early systemic sclerosis (2004) J Rheumatol, 31, pp. 1941-1945
dc.descriptionBernardo, P., Conforti, M.L., Bellando-Randone, S., Pieragnoli, P., Blagojevic, J., Kaloudi, O., Implantable
dc.publisher
dc.relationRevista Brasileira de Reumatologia
dc.rightsfechado
dc.sourceScopus
dc.titleRecommendations For The Management And Treatment Of Systemic Sclerosis [recomendações Sobre Diagnóstico E Tratamento Da Esclerose Sistêmica]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución